Redmile Group LLC decreased its stake in shares of CeriBell, Inc. (NASDAQ:CBLL – Free Report) by 11.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 386,786 shares of the company’s stock after selling 48,453 shares during the quarter. CeriBell accounts for about 0.5% of Redmile Group LLC’s investment portfolio, making the stock its 25th biggest position. Redmile Group LLC’s holdings in CeriBell were worth $7,090,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in CBLL. Caitong International Asset Management Co. Ltd lifted its stake in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the period. Strs Ohio acquired a new position in CeriBell in the 1st quarter valued at approximately $27,000. CWM LLC raised its holdings in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the period. Finally, Larson Financial Group LLC lifted its position in shares of CeriBell by 1,403.1% in the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after acquiring an additional 2,680 shares during the period.
Analyst Ratings Changes
A number of research analysts recently commented on CBLL shares. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Canaccord Genuity Group lowered their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.
Insiders Place Their Bets
In other CeriBell news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $20.12, for a total value of $4,071,644.16. Following the sale, the insider directly owned 3,765,054 shares in the company, valued at $75,752,886.48. This represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CTO Raymond Woo sold 1,966 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $18.00, for a total value of $35,388.00. Following the transaction, the chief technology officer owned 195,682 shares of the company’s stock, valued at $3,522,276. This represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 350,789 shares of company stock worth $6,946,191 over the last quarter. Corporate insiders own 20.10% of the company’s stock.
CeriBell Stock Down 1.7%
Shares of CBLL opened at $17.83 on Wednesday. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $18.59 and a two-hundred day moving average price of $19.35. The stock has a market cap of $676.47 million, a price-to-earnings ratio of -10.94 and a beta of 0.77. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33.
CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. Equities analysts predict that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.
CeriBell Company Profile
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Read More
- Five stocks we like better than CeriBell
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell, Inc. (NASDAQ:CBLL – Free Report).
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
